Headway closed a $125 million Series C funding round. The round brings the New York-based startup’s valuation to $1 billion, reaching unicorn status. The company connects patients to in-network therapists and helps mental health providers avoid the massive administrative burden associated with taking insurance.
Digital health's investment slowdown is so severe that the fourth quarter of 2022 marked the lowest quarterly digital health funding total in the past five years, according to new report. Q4 was also the first quarter with no new unicorn births since 2018.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
There are currently 97 global digital health companies that are considered unicorns. But getting caught up with the idea of digital health unicorns isn’t very sustainable, according to Emilly Melton, managing partner at Threshold Ventures. Instead of focusing too much on their valuations, she recommended that startups simply focus on getting the capital they need in order to reach the next stage of inflection.
The company, which provides telemedicine and digital programs focused on maternal health, will use the funds raised to expand its services to new populations, including international patients and Medicaid members.
The health technology company's valuation skyrocketed to $1.3 billion following its latest funding round. It plans to use the new funds to launch Innovaccer Health Cloud, which will aggregate and normalize data from different systems and support the development of interoperable apps.
The newly crowned unicorn's insurance product enables members to shop for medical services and pay directly for care. The company raised $125 million in a recent funding round, boosting its valuation, which it will use to increase its footprint and launch new products.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Through the round led by OrbiMed, the Salt Lake City data analytics company has become a healthcare unicorn.
As of late October, healthcare's newest unicorn - Butterfly Network - has begun shipping its ultrasound-on-a-chip system that a senior executive believes will alter the field of ultrasound forever.
Here's how the Chicago startup that raised $500 million and accorded unicorn status stumbled amidst charges of deception, and what the task ahead is for its newly-appointed CEO from the advertising world.
In a statement, the cofounders of Outcome Health contended that the equity investors led by Goldman Sachs are misusing the court system,
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Zenefits survived as a unicorn despite a major devaluation in 2016. Theranos did not. Human Longevity and Flatiron Health joined the exclusive club.
A shortage of liquidity opportunities is leaving tech unicorns with paper valuations that late-stage private financiers are now less eager to cleanly finance.
So much news continues to emerge about Theranos. First it was hype, and now it's notice of decline. So we've compiled a handy — and highly comprehensive — timeline (doomsday clock) of the erstwhile unicorn.